This is an HTML version of an attachment to the Official Information request 'What are the Commercially Reasonable Efforts in the Pfizer supply contract'.

 
133 Molesworth Street 
PO Box 5013 
Wellington 6140 
New Zealand 
T+64 4 496 2000 
 
26 April 2023 
 
 
Erika Whittome 
 
By email:  [FYI request #22471 email] 
Ref:   
H2023023609 
 
 
Tēnā koe Erika 
 
Response to your request for official information 
 
Thank you for your request under the Official Information Act 1982 (the Act) to Manatū Hauora 
(the Ministry of Health) on 16 April 2023. You requested:  
 
“Please would you share the “Commercially Reasonable Efforts” details on the 
contract you have  with Pfizer for supplying  Comirnaty to New Zealand.
 
  
I request the details in this contract on the efforts Pfizer are delivering 
as part of this contract  on 
1 Medicine safety, 
2 Medicine efficacy and 
3 pharmocovil igance.” 
The contracts between Pfizer and the New Zealand Government are withheld in full under the 
following sections of the Act: 
•  Section 9(2)(b)(ii) as its release would likely unreasonably prejudice the commercial 
position of the person who supplied the information.    
•  Section 9(2)(ba)(ii) to protect information that is subject to an obligation of confidence 
and making it available would likely damage the public interest.  
I have considered the countervailing public interest in release in making this decision and 
consider that it does not outweigh the need to withhold at this time. However, information 
regarding the safety and effectiveness of the vaccine can be found on the Ministry of Health 
website at the following links:  
•  The Coronavirus Immunisation handbook: www.health.govt.nz/our-work/immunisation-
handbook-2020/5-coronavirus-disease-covid-19. This also provides references to 
scientific studies conducted regarding COVID-19 and the vaccine.  
•  The vaccine datasheet: www.medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf  
•  Medsafe also publishes up to date information regarding the Comirnaty vaccine, 
including its clinical efficacy and safety: 
www.medsafe.govt.nz/profs/PUArticles/June2021/Spotlight-on-Comirnaty-vaccine.html.  
•  Manatū Hauora webpage regarding vaccine safety and efficacy: www.health.govt.nz/our-
work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-vaccines/covid-19-
vaccine-effectiveness-and-protection.
 


•  Manatū Hauora Science News page for up to date information regarding COVID-19 and 
the Vaccine: www.health.govt.nz/our-work/diseases-and 
•  Information about Medsafe’s process for vaccine safety monitoring: 
www.medsafe.govt.nz/COVID-19/monitoring-process.asp. 
Furthermore, independent safety monitoring has also been in place since February 2021 to 
monitor and provide advice on the safety of COVID-19 vaccines. More information can be found 
here: www.health.govt.nz/covid-19-novel-coronavirus/covid-19-vaccines/covid-19-vaccine-
information-health-professionals/covid-19-vaccine-strategy-planning-insights/covid-19-who-
were-working#ismb.
 
 
Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any 
decisions made under this request. The Ombudsman may be contacted by email at: 
[email address] or by calling 0800 802 602. 
 
Nāku noa, nā 
 
 
 
 
 
Jan Torres 
Manager, OIA Services  
Government and Executive Services l Te Pou Whakatere Kāwanatanga 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Page 2 of 2